Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells

Gynecologic Oncology

Volumn 81, Issue 3, 2001, Pages 380-390

  Cuello, Mauricio ^a,b   Ettenberg, Seth A ^a,b   Nau, Marion M ^a,c   Lipkowitz, Stan ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Apoptosis; Chemotherapy; Ovarian cell line; TRAIL

Indexed keywords

CASPASE; CISPLATIN; DOXORUBICIN; PACLITAXEL; RIBONUCLEASE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; ENZYME ASSAY; EPITHELIUM CELL; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; NICK END LABELING; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0034985464     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6194     Document Type: Article

References (68)

1. Cancer statistics 1999
2. Update of the NCCN ovarian cancer practice guidelines
3. Advanced epithelial ovarian cancer: 1998 consensus statements
4. Chemotherapy resistance in ovarian cancer: New molecular perspectives
5. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines
6. Clinical study of multi-drug resistance gene (MDR1) expression in primary ovarian cancer
7. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer
8. Mechanisms of drug resistance in ovarian cancer
9. Loss of DNA mismatch repair in acquired resistance to cisplatin
10. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer
11. Multiple drug resistance parameter expression in ovarian cancer
12. Mechanism-based target identification and drug discovery in cancer research
13. The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms
14. Biological therapy of ovarian cancer: Current directions
15. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
16. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin)
17. Death receptors: Signaling and modulation
18. Apoptosis signaling by death receptors
19. Mechanisms of apoptosis
20. Apoptosis control by death and decoy receptors
21. Control of apoptosis signaling by Apo2 ligand
22. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
23. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
24. TRAIL kills cancer cells, but not normal cells
25. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity
26. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
27. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies
28. TRAIL death pathway expression and induction in thyroid follicular cells
29. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
30. Molecular determinants of response to TRAIL in killing of normal and cancer cells
31. IAP family proteins - Suppressors of apoptosis
32. Regulation of TRAIL-induced apoptosis by transcription factors
33. NF-kB and TRAIL mediated apoptosis in breast cancer cell lines
34. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
35. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells
36. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines
37. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture
38. Effects of more than one inhibitor
39. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
40. Cell death: TRAIL and its receptors
41. The caspase family of cysteine proteases
42. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
43. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
44. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha
45. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells
46. Drug resistance in ovarian cancer: From the laboratory to the clinic
47. Drug resistance in ovarian cancer - The role of p53
48. p53 in signaling checkpoint arrest or apoptosis
49. Mechanisms of p53-mediated apoptosis
50. Spontaneous development of drug resistance: Mismatch repair and p53 defects in resistance to cisplatin in human tumor cells
51. Role of p53 in drug resistance in ovarian cancer
52. Overexpression and mutation of p53 in epithelial ovarian cancer
53. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma
54. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas
55. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato) (dichloro)-platinum(IV)
56. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status
57. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest
58. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
59. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines
60. p21 (WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4
61. Death and decoy receptors and p53-mediated apoptosis
62. Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells
63. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II)
64. Protein binding of anthraquinone glycosides, with special reference to adriamycin
65. The taxoids. Comparative clinical pharmacology and therapeutic potential
66. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
67. Intraperitoneal therapy in the management of ovarian carcinoma
68. Phase I trial of intraperitoneal Taxol: A Gynecoloic Oncology Group study